Alessandra Fontecedro-Curioni

Fribourg, FR, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

Low baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma.

Low baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 07, 2026

Multiplexed single-cell and spatial profiling reveal B cells and tertiary lymphoid structures as prognostic indicators in pleural mesothelioma.

Multiplexed single-cell and spatial profiling reveal B cells and tertiary lymphoid structures as prognostic indicators in pleural mesothelioma.

Journal: British journal of cancer

Published: October 07, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2025

Pleural mesothelioma.

Pleural mesothelioma.

Journal: Nature reviews. Disease primers

Published: July 14, 2025

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Journal: ESMO open

Published: July 11, 2025

Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

Journal: JCO precision oncology

Published: February 12, 2025

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Journal: Nature medicine

Published: January 27, 2025

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2024

CD26 as a potential therapeutic target for lung adenocarcinoma.

CD26 as a potential therapeutic target for lung adenocarcinoma.

Journal: Frontiers in oncology

Published: December 28, 2024

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 05, 2024

Acquired resistance to immunotherapy in solid tumors.

Acquired resistance to immunotherapy in solid tumors.

Journal: Trends in molecular medicine

Published: November 28, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026